Publication | Open Access

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Checkmate 063Single-arm TrialMedicineImmunologyImmune Checkpoint InhibitorCancer TreatmentPhase 2ImmunotherapyOncologyRadiation OncologyLung Cancer